Theriva Biologics (TOVX) Accumulated Depreciation (2018 - 2026)
Theriva Biologics (TOVX) posted quarterly Accumulated Depreciation of $981000.0 for Q1 2026, up 0.82% year-over-year from $973000.0 in Q1 2025, and up 1.55% quarter-over-quarter from $966000.0 in Q4 2025.
Theriva Biologics (TOVX) Accumulated Depreciation (2018 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Accumulated Depreciation for 9 consecutive years, with $981000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Depreciation rose 0.82% year-over-year to $981000.0; the TTM figure through Mar 2026 stood at $981000.0 (up 0.82% YoY), while the FY2025 annual figure was $966000.0, up 3.32% from the prior year.
- Accumulated Depreciation improved to $981000.0 in Q1 2026 per TOVX's latest filing, from $966000.0 in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $1.2 million in Q1 2022 and bottomed at $813000.0 in Q2 2022.
- Historically, Accumulated Depreciation has averaged $951176.5 across 5 years, with a median of $959000.0 in 2023.
- On a YoY basis, Accumulated Depreciation climbed as much as 15.84% in 2023 and fell as far as 22.27% in 2023.
- Theriva Biologics' Accumulated Depreciation stood at $865000.0 in 2022, then increased by 15.84% to $1.0 million in 2023, then dropped by 6.69% to $935000.0 in 2024, then grew by 3.32% to $966000.0 in 2025, then grew by 1.55% to $981000.0 in 2026.
- Business Quant data shows TOVX's Accumulated Depreciation at $981000.0 in Q1 2026, $966000.0 in Q4 2025, and $988000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.00 Mn |
| Mar 31, 2026 | 981,000.00 |
| Dec 31, 2025 | 966,000.00 |
| Sep 30, 2025 | 988,000.00 |
| Jun 30, 2025 | 1.02 Mn |
| Mar 31, 2025 | 973,000.00 |
| Dec 31, 2024 | 935,000.00 |
| Sep 30, 2024 | 927,000.00 |
| Jun 30, 2024 | 884,000.00 |
| Mar 31, 2024 | 1.04 Mn |
| Dec 31, 2023 | 1.00 Mn |
| Sep 30, 2023 | 959,000.00 |
| Jun 30, 2023 | 930,000.00 |
| Mar 31, 2023 | 897,000.00 |
| Dec 31, 2022 | 865,000.00 |
| Sep 30, 2022 | 835,000.00 |
| Jun 30, 2022 | 813,000.00 |
| Mar 31, 2022 | 1.15 Mn |
| Dec 31, 2021 | 831,000.00 |
| Sep 30, 2021 | 817,000.00 |